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Short title:   Gas6, VTE recurrence and mortality in the elderly 
 
 
 
Scientific category:  Thrombosis and Hemostasis 
 
 
 
ESSENTIALS 
 
 Predictive ability of pro-hemostatic Gas6 for recurrent venous thromboembolism (VTE) 
is unknown. 
 We measured Gas6 levels in 864 patients with VTE over 3 years. 
 High Gas6 (>157%) at diagnosis is associated with VTE recurrence, major bleeding and 
mortality. 
 Gas6 plasma levels measured 12 months after the index VTE are discriminatory for 
VTE recurrence. 
 
SUMMARY 
BACKGROUND: Growth arrest-specific gene 6 (Gas6) is a pro-hemostatic protein with an 
unknown predictive ability for recurrent venous thromboembolism (VTE). In the elderly, VTE 
carries a higher mortality but not a higher rate of VTE recurrence than in younger patients. 
Consequently, anticoagulation management in the elderly is challenging. 
 
OBJECTIVE: To prospectively investigate the performance of Gas6 to predict VTE 
recurrence, major bleeding and mortality in the elderly. 
 
METHODS: Consecutive patients aged ≥65 with acute VTE were followed over 3 years. 
Primary outcomes were symptomatic VTE recurrence, major bleeding and mortality. 
Plasmatic Gas6 was measured by ELISA. 
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RESULTS: Gas6 was measured in 864 patients at the time of the index VTE (T1) and in 70% 
of them, also 12 months later (T2). Gas6 at T1 was discriminatory for VTE recurrence (C-
statistics: 0.56, 95% confidence interval [CI]: 0.51 to 0.62), major bleeding (0.60, 95%CI: 
0.55 to 0.65) and mortality (0.69, 95%CI: 0.65-0.73) up to 36 months. VTE recurrence up to 
24 months after T2 was discriminated by Gas6 at T2 (0.62, 95%CI: 0.54-0.71). High Gas6 
(>157%) and continuous Gas6 levels at T1 were associated with VTE recurrence up to 6 
and 12 months, respectively. 
 
CONCLUSIONS: In elderly patients, high Gas6 is associated with a higher risk of VTE 
recurrence, major bleeding and death. These findings support urther studies to assess the 
performance of Gas6 for adjusting anticoagulation length. 
 
INTRODUCTION 
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary 
embolism (PE), represents a worldwide major health issue and is a leading cause of 
cardiovascular death.(1) VTE incidence rises with age.(2-5) In the elderly population, VTE 
carries a higher mortality but not a higher rate of recurrence than in younger patients.(4) 
Elderly patients more often present comorbidities and therefore higher risk of bleeding.(4) 
Consequently, the management of the anticoagulation in the elderly constitutes a challenge.  
 
Because the risk of VTE recurrence is greatest in the first 6-12 months following the initial 
event and progressively decreases afterwards,(6) the benefit of extended anticoagulation 
may be exceeded by the risk of clinically important bleeding.(7-12) 
 
Growth arrest-specific gene 6 (Gas6), the product of the growth arrest-specific gene 6 
(GAS6),(13) is a secreted vitamin K-dependent protein. Gas6 plasma level is known to be 
elevated in a variety of clinical conditions including inflammation or sepsis,(14-18) 
obesity,(19) chronic renal failure and cancer.(20) Importantly, no change in Gas6 plasma 
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level was previously observed with increasing age.(21) Nevertheless, Gas6 level 
progressively decreased with increasing INR under warfarin therapy.(21) 
 
Gas6 exerts multiple functions, including regulation of cell-growth(13) and inflammation.(22) 
It also has effect on platelet function and coagulation, enhancing platelet aggregation and 
tissue factor expression in endothelial cells as well as promoting the recruitment of platelets 
and leukocytes to the endothelial cell membrane.(23-28) In mice, the absence of Gas6 is 
protective against thrombosis without causing excessive bleeding, pointing to Gas6 as an 
attractive target for antithrombotic therapy.(23, 25)  
 
In a cross-sectional study including 279 patients and 79 controls, Blostein et al.(29) 
measured a higher Gas6 plasma level in patients 4 months after VTE than in healthy 
controls. In addition, they observed that subjects with elevated Gas6 level in plasma had an 
increased risk of VTE compared to those with lower Gas6 levels after adjustment for age, 
sex, medications and comorbidities. However, elevated Gas6 plasma levels were not 
predictive of VTE recurrence.(29) Finally, most of the patients included in this study were 
younger than 65 years. 
 
Here, in a cohort of 864 patients aged 65 years or older with VTE, we prospectively 
investigated the performance of Gas6 plasma levels at admission and one year after the 
index VTE to predict the risk of VTE recurrence, major bleeding and mortality. 
 
METHODS 
Cohort sample 
The study was conducted between September 2009 and December 2013 as part of the 
Swiss Cohort of Elderly Patients with VTE (SWITCO65+), a prospective multicenter cohort 
study to assess medical outcomes and quality of life in elderly patients with acute VTE from 
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all five university hospitals and from four high-volume non-university hospitals in 
Switzerland.(30) 
 
Consecutive patients aged 65 years or older with acute VTE were identified in the in- and 
outpatient services of all participating study sites, and followed over 3 years. We defined 
deep vein thrombosis (DVT) as an acute onset of leg pain or swelling plus incomplete 
compressibility of a venous segment on ultrasonography or an intraluminal filling defect on 
contrast venography.(31) 
 
Because iliac veins and the inferior vena cava may be technically difficult to compress, 
additional diagnostic criteria for iliac/caval DVT comprised abnormal duplex flow patterns 
compatible with thrombosis or an intraluminal filling defect on spiral computed tomography 
or magnetic resonance imaging venography.(32-34) 
 
Given that ultrasonography has a reduced sensitivity and specificity for distal DVT,(35) 
patients with isolated distal DVT were included only if the incompressible distal deep vein 
transverse diameter was at least 5 mm.(36, 37)  
 
Symptomatic pulmonary embolism (PE) was defined as an acute onset of dyspnea, chest 
pain, or syncope coupled with a new high-probability ventilation/perfusion lung scan; a new 
contrast filling defect on spiral computed tomography or pulmonary angiography; or the new 
documentation of a proximal DVT either by venous ultrasound or contrast venography.(37, 
38) Radiographic studies used to diagnose VTE were interpreted by on-site vascular 
specialists or radiologists. 
 
Exclusion criteria were inability to provide informed consent (i.e. severe dementia), 
conditions incompatible with follow-up (i.e. terminal illness or place of living too far from the 
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study center), insufficient German- or French-speaking ability, thrombosis at a site other 
than a lower limb, catheter-related thrombosis. 
 
Treatment of VTE, e.g., the type of anticoagulant used (i.e. parenteral anticoagulant followed 
by vitamin K antagonists, parenteral anticoagulant alone, direct oral anticoagulant), the 
duration of the anticoagulation and the prescription of compression stocking, was entirely left 
to the discretion of the managing physicians. 
 
Eligible patients were approached for informed consent to participate in the study. The ethics 
committees at each study site approved the study, and written informed consent was 
obtained from all participants. A detailed description of the study methods has previously 
been published.(30)  
 
Data collection 
For all enrolled patients, trained study nurses prospectively collected baseline demographic 
information (age, sex), type, history and complication of VTE (distal DVT, proximal DVT, 
overt PE, presence of post-thrombotic syndrome, prior VTE, provoked index VTE, cancer-
related VTE), concomitant use of estrogen therapy during the past 3 months, immobilization 
during the last 3 months, major surgery during the last 3 months, comorbid conditions 
(history of major bleeding, chronic liver disease, renal disease, chronic or acute heart failure, 
cerebrovascular disease, diabetes mellitus, body mass index > 30, acute rheumatic disease 
during the last 3 months, inflammatory bowel disease, severe infection or sepsis during the 
last 3 months), high risk of fall, laboratory findings (anemia, low platelet count), concomitant 
use of antiplatelet drugs, arterial hypertension, heart rate ≥ 110 beats/min, systolic blood 
pressure < 100 mmHg, respiratory rate ≥ 30/min, temperature < 36°C, arterial oxygen 
saturation < 90% and VTE-related treatment using standardized data collection forms. 
Follow-up included one telephone interview and two face-to-face evaluations during the first 
year of study participation and then semi-annual contacts, alternating between face-to-face 
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evaluations (clinic visits or home visits in house-bound patients) and telephone calls as well 
as periodic reviews of the patient’s hospital chart. During each visit/contact, study nurses 
interviewed patients to obtain information about the date and type of clinical events 
(recurrent VTE, bleeding, death). If a clinical event had occurred, this information was 
complemented by reviewing medical charts and interviewing patients’ primary care 
physicians and family members. Collected data were recorded on standardized forms. 
 
Blood samples 
Blood was collected after minimal venostasis into 1/9 of its volume of 0.0160 M trisodium 
citrate (Sarstedt®) at the time of index VTE diagnosis and 12 months later.(39) Citrated 
platelet poor plasma (PPP) was prepared by centrifugation for 10 minutes at 2700 g and 
room temperature and recentrifugation of the supernatant plasma for 10 minutes at 2700 g 
to remove remaining platelets.(39) The resulting citrated PPP was stored in aliquots of 2 mL 
at -80°C within 1 hour of blood collection.(39) Citrated PPP was used for Gas6 ELISA.   
 
Gas6 ELISA 
To measure Gas6, we used the ELISA method developed by Clauser et al(40) with some 
modifications.(17) Wells from 96-wells plates (Maxisorp, Nunc) were coated with 100 μL per 
well of polyclonal goat anti-human Gas6 antibody (AB885, R&D Systems) diluted in 0.1M 
NaHCO3 pH 8.2 and incubated overnight at 4°C. After two washes with PBS-Tween 0.05%, 
100 μL PBS-BSA 1%- sucrose 5% were added to the wells and plates were incubated 2 
hours at room temperature. After three washes samples diluted 50 and 100 times and 
normal plasma serial dilution with PBS-BSA 1% were added to the wells, followed by an 
overnight incubation at 4°C. After three washes, 100 μL of biotinylated polyclonal goat 
antibody (BAF885, R&D Systems) were added to each well, and plates left 2 hours at room 
temperature. Signal was amplified with Avidin-horseradisch-peroxidase (BD Pharmingen) 
and plates incubated during 20 minutes at 37°C. Finally, o-phenylenediamine 
dihydrochloride (Sigma-Aldrich) was added. Reactions were stopped by adding 50 μL HCl 
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3M. Absorbance was measured at 492 nm and results were expressed in percentage 
relative to normal plasma, using its serial dilution as standard curve.(17, 40) This ELISA was 
specific for human Gas6, with no cross-reactivity with human protein S. 
 
D-dimer  
D-dimer was measured by ELISA (Vidas D-dimer exclusion test, bioMérieux). 
 
Outcome variables 
We defined objectively confirmed, symptomatic VTE recurrence, major bleeding and overall 
mortality up to 3 years as primary study outcomes. 
 
VTE recurrence was defined as a fatal or new non-fatal PE or new DVT.(41) Diagnosis of 
recurrent VTE during follow-up was established with the following criteria: for DVT, on the 
basis of abnormal results on ultrasonography; and for PE, on the basis of CT or angiography 
showing new intraluminal defects or on the basis of ventilation-perfusion lung scan showing 
a high-probability pattern with new perfusion defects. A new proximal DVT, based on 
abnormal results on ultrasonography, associated with new PE symptom(s) (shortness of 
breath, chest pain, syncope) was also considered as recurrent pulmonary embolism. 
 
Major bleeding was defined as fatal bleeding, symptomatic bleeding at critical sites 
(intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or 
intramuscular with compartment syndrome), or a clinically overt bleeding with a reduction of 
hemoglobin of at least 20 g/L, or leading to transfusion of 2 or more units of packed red 
blood cells.(42) 
 
We assessed the outcomes using patient or proxy interviews, interview of the patient’s 
primary care physician, and/or hospital chart review.(30) A committee of 3 blinded clinical 
experts confirmed all outcomes and classified the cause of all deaths as definitely due to PE, 
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possibly due to PE (e.g., sudden death without obvious cause), due to major bleeding or due 
to another cause.(30) Final classification was made on the basis of the full consensus of this 
committee.(30)  
 
Statistical analyses 
We compared baseline characteristics of patients by elevated plasma Gas6 (above versus 
below median) using the Chi-squared test and the non-parametric Wilcoxon rank-sum test 
as appropriate. We calculated incidence rates of a first VTE recurrence, a first major 
bleeding or death up to three years after the index event by level of Gas6. Gas6 was 
categorized into low, medium, and high levels based on their lower and upper quartiles. We 
estimated the cumulative incidence of these outcomes using the Kaplan-Meier method and 
compared survivor functions across groups by the logrank test.  
 
The discriminative power of Gas6 for VTE recurrence, major bleeding and mortality was 
assessed by Harrell’s C concordance statistic. 
 
Associations between Gas6 and the time to a first VTE recurrence and major bleeding were 
assessed by competing risk regression accounting for non-PE and non-bleeding related 
death, respectively, as a competing event, according to the method of Fine and Gray.(43) 
The method yields subhazard ratios (SHR) with corresponding 95%-confidence intervals (CI) 
and P-values for the failure event of primary interest. For mortality, an ordinary Cox-
regression with robust standard errors was calculated. We adjusted the model for previously 
published predictors of VTE recurrence or major bleeding.(6, 41, 42, 44-52) For overall 
mortality, analyses were adjusted for age, gender, cancer, provoked VTE, prior VTE, overt 
PE, renal disease, history of major bleeding, heart failure, chronic lung disease, elevated 
heart rate, low blood pressure, low oxygen, and periods of anticoagulation as a time-varying 
covariate.(49, 53) 
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All analyses were done using Stata 14 (Stata Corporation). 
 
RESULTS 
Study sample 
Of 1003 enrolled patients aged ≥ 65 years with acute VTE, we excluded 139 patients at the 
time of index VTE diagnosis (8 patients did not allow use of data, 4 withdrew their consent 
within 1 day and 127 patients had no Gas6 measurement) leaving a study sample of 864 
patients (Fig. 1). Of these patients, 601 (69.6%) had Gas6 measurement 12 months after the 
index VTE.  
 
Characteristics at time of index VTE diagnosis are listed in Table 1. Overall, 476 patients 
(44.9%) were women and the median age was 75.0 (interquartile range, IQR 69.0 ; 81.0). 
599 patients (69.3 %) presented with an index PE. 251 patients (29.1%) had experienced 
prior VTE. 522 patients (60.4%) had unprovoked index VTE, 185 (21.4%) had provoked VTE 
and 157 (18.2%) had cancer-related VTE. Patients with unprovoked index VTE or with prior 
VTE were more susceptible to present with PE (70%) than with proximal (24%) or distal DVT 
only (6%). PE was more frequent in patients with unprovoked VTE (72%), than in patients 
with provoked (66%) or cancer related (64%) VTE (P = 0.01). Twelve months after index 
VTE, 432 patients (50%) were still under anticoagulation, most of them receiving vitamin K 
antagonists. 
 
Gas6 plasma levels in study sample 
At the time of index VTE diagnosis, median Gas6 level was 129.3% (IQR 108.9, 156.6) (T1 
on Fig. 2). Patients with elevated Gas6 level (> 129%) at the time of index VTE were slightly 
older (median age 76 versus 74, P = 0.001). However, the correlation between Gas6 level 
and age was weak both at the time of the index VTE (Spearman correlation, rs = 0.12) and 
12 months later (rs = 0.09). Patients with elevated Gas6 at the time of the index VTE 
diagnosis were more likely to have cancer-related VTE. They were also more immobilized 
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during the last 3 months and displayed a higher prevalence of post-thrombotic syndrome, 
history of major bleeding, anemia, thrombocytopenia, heart rate ≥ 110 beats/min and oxygen 
saturation < 90% (Table 1). In contrast, these patients were less likely to be still under oral 
anticoagulation 12 months after index VTE (180 [41.4%] patients with Gas6 above median 
versus 230 [53.6%] patients with Gas6 below or at median, P < 0.001). Interestingly, patients 
with inflammatory bowel disease were more likely to have a lower Gas6 level (P = 0.016). 
Twelve months after the index VTE, median Gas6 level was 93% (IQR 77.1, 111.7) (T2 on 
Fig. 2). However, at this time point, median Gas6 was lower in patients on than in patients 
off anticoagulation (86.1% [IQR 70.4, 107.3] versus 100.2% [IQR 85.3, 116.8], P < 0.001). 
 
Gas6 plasma levels were generally lower 12 months after the index VTE (T2) than those at 
the time of the index VTE (T1’ versus T2, P < 0.001, Fig. 2). In a minority of patients (n = 97, 
11%), Gas6 increased from VTE diagnosis to 12 months after. 
 
The correlation between Gas6 and D-dimer was weak, both at time of the index VTE 
(Spearman correlation, rs = 0.06) and 12 months later (rs = 0.24).  
 
Incidence of VTE recurrence, major bleeding and mortality 
After a follow-up of 3 years, 100 patients had developed recurrent VTE, resulting in an 
incidence rate of 5.6 per 100 person-years (95% confidence interval [CI] 4.6 to 6.8). During 
the same period, 170 of 864 patients had died (mortality rate 9.0 per 100 person-years; 95% 
CI 7.8 to 10.5). Mortality rate was higher during the initial 6 months whereas VTE recurrence 
rate remained stable over the observation-period (Table S1). During the whole follow-up, 
incidence rates of VTE recurrence and major bleeding were higher in patients with high 
Gas6 level than in patients with medium or low Gas6 levels measured at the time of the 
index VTE (Table S1). Likewise, the 2-year cumulative incidence of VTE recurrence was 
higher for patients with high (> 157%) versus medium (109-157%) and low (< 109%) Gas6 
levels measured at the time of the index VTE, however not significantly (P = 0.087) (Fig. 3A). 
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The 2-year cumulative incidence of major bleeding was higher for patients with high (> 
157%) versus medium (109-157%) and low (< 109%) Gas6 levels measured at the time of 
the index VTE (P = 0.0004) (Fig. 3B). 
 
The 2-year cumulative incidence of overall mortality was 7%, 15% and 35% (P < 0.001) for 
patients with a low, medium and high Gas6 level, respectively (Fig. 3C).  
   
Discriminative power of Gas6 levels for outcomes 
In order to evaluate the discriminative power of Gas6 levels, C-statistic (95%-CI) values 
were calculated (Table 2). Gas6 level measured at the time of the index VTE were 
discriminatory for VTE recurrence, major bleeding and mortality up to 36 months.  
 
Gas6 level measured 12 months after the index VTE was discriminatory for VTE recurrence 
up 24 months. In contrast, when measured 12 months later, Gas6 level was not 
discriminatory for major bleeding and mortality up to 24 months (Table 2). 
 
Association between Gas6 plasma level and outcomes 
High Gas6 levels (> 157%) measured at the time of the index VTE were associated with 
increased risk of VTE recurrence up to 6 months (Table 3), and major bleeding up to 36 
months (crude analysis) (Table 4) . In continuous analysis (log-transformed Gas6 levels), the 
risk of VTE-recurrence  was increased up to 12 months (Table 3), and the risk of major 
bleeding up to 36 months (crude analysis) (Table 4).  
 
In addition, medium (109-157%) and high Gas6 levels were associated with increased 
overall mortality up to 36 months (Table 5).  
 
These associations also remained after adjustment for potential confounding factors for the 
risk of VTE recurrence and overall mortality (Table 3 and 5). 
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Regarding the risk of major bleeding, only the association with high Gas6 measured at the 
time of the index VTE remained up to 6 months after adjustment for potential confounding 
factors (Table 4). 
 
We assessed the relationship  between  continuous log-transformed Gas6 values and 
hazards of VTE recurrence and overall mortality using fractional polynomial competing risk 
and Cox proportional hazards models, which showed that (sub)-hazards augmented with 
increased Gas6 values in a linear way (Supplementary Figure). 
 
The findings of the sensitivity analyses revealed that these associations also remained after 
the exclusion of patients with cancer (Table S2 or with cancer and provoked VTE (Table S3). 
Moreover, in the subgroup of patients off of oral anticoagulation 12 months after the index 
VTE, continuous (log-transformed) Gas6 levels were associated with VTE recurrence up to 
12 months (Table S4). This association also remained after adjustment for potential 
confounding factors (Table S5). Finally, medium, high and continuous (log-transformed) 
Gas6 levels were associated with increased mortality up to 36 months (Table 5).  
 
DISCUSSION 
We followed prospectively 864 elderly patients with VTE over 3 years and observed that 
patients with higher Gas6 were more likely to have cancer-related VTE and co-morbidities. 
Our findings are consistent with previous publications reporting high Gas6 levels in a 
number of clinical conditions, most of them associated with inflammation and organ damage 
(14, 17, 54, 55).  
 
Our data showed that elevated Gas6 was independently associated with recurrent VTE up to 
12 months, with major bleeding up to 6 months and with mortality up to 36 months after the 
index VTE. Considering that patients with more comorbidities were more likely to have 
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higher Gas6 levels, neither the association with VTE recurrence, major bleeding nor overall 
mortality was surprising. However, the observed association remained significant after 
adjustment for a large number of comorbidities (Table 3-5). Gas6 was also still associated 
with VTE recurrence and mortality after the exclusion of patients with cancer (Table S2) or 
with cancer and provoked VTE (Table S3). Because Gas6 is a pro-hemostatic protein (23-
25), we may presume that the association between high Gas6 levels and VTE recurrence 
might be at least partly causal.  
 
Another important finding of this study is that Gas6 levels measured at the time of diagnosis 
were discriminatory for VTE recurrence and mortality. In addition, Gas6 levels measured 12 
months after the index VTE were discriminatory only for VTE recurrence. A previous study 
comprising a lower number of patients than this study did not demonstrate the predictive 
ability of Gas6 for VTE recurrence (29).Thus, the data of the present study point to elevated 
Gas6 level as an independent predictor for VTE recurrence, major bleeding and mortality up 
to 36 months in the elderly. Gas6 might be then useful in adjusting the intensity of 
surveillance in this group of high-risk patients. However, before considering Gas6 as an 
additional marker to predict recurrence and guide therapy, Gas6 level would need to be 
compared with or integrated in established risk scores such as DASH,(56) HERDOO-2,(57) 
Vienna(58) scores. 
 
Our study has some limitations. First, the spectrum of the study was limited to elderly 
patients and 18.2% of them had cancer, the mortality from comorbid diseases is naturally 
higher than the VTE recurrence rate, as persons with limited life expectancy often do not 
have the time to develop recurrent VTE. Thus, it is indeed unclear whether the results can 
be extrapolated to younger persons with VTE. In addition, although Gas6 plasma level was 
previously reported not to be influenced by age,(21) its prediction ability for VTE recurrence 
as well as its association with VTE recurrence would need to be studied in younger patients. 
Second, Gas6 was previously reported to be elevated in several other medical conditions. 
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Nevertheless, in this study, we were able to demonstrate that the association between Gas6 
and VTE recurrence and mortality remained after adjustment for these conditions. However, 
this needs to be verified in younger patients. Third, VTE treatment has changed since this 
cohort has been constituted, i.e. direct oral anticoagulants have replaced vitamin K 
antagonists in most patients. Therefore, it is unclear whether the results can be extrapolated 
to patients treated by direct oral anticoagulants. Fourth, as we have enrolled patients with 
VTE in in- and outpatients hospital services, the proportion of patients with pulmonary 
embolism was relatively high and represented 69% of our study sample. Fifth, Gas6 testing 
was performed only at the time of the index VTE and 12 months later, when about 50% of 
the patients were still under oral anticoagulation. Because we and others(21) demonstrated 
that Gas6 levels are affected by oral anticoagulation by vitamin K antagonists, we can 
assume that the significantly lower Gas6 level 12 months after the index VTE was at least 
partly due to the antivitamin K effect. Interestingly, Gas6 levels in the subgroup of patients 
off of oral anticoagulation at this time point were significantly lower than those of patients on 
anticoagulation. Thus, the correct interpretation of Gas6 levels would require that patients 
interrupt anticoagulation, exposing those with increased risk to the possibility of a VTE 
recurrence. Finally, even though we adjusted our analyses for many covariates, we might 
have missed important predictor variables.  
 
In conclusion, in the elderly, high Gas6 is associated with a higher risk of VTE recurrence, 
major bleeding but only up to 6 months, a period of time where most patients were still 
anticoagulated, and death. Our data suggest that a clinical decision to avoid prolonged 
anticoagulation could be attempted based on Gas6 plasma level in the elderly. Further 
studies are required to confirm whether the use of Gas6 levels for adjusting anticoagulation 
length leads to better outcomes, especially in younger patients. 
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ADDENDUM 
A. Schnegg-Kaufmann, S. Calzavarini and A. Angelillo-Scherrer designed the protocol and 
the analyses plan, conducted the analyses and drafted the manuscript. S. Calzavarini 
performed Gas6 measurements. A. Limacher performed the statistical analysis. A. Schnegg-
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FIGURE LEGENDS 
 
Figure 1. Flow diagram of patients included in the study 
VTE, venous thromboembolism 
 
Figure 2. Gas6 plasma levels at the time of VTE diagnosis and 12 months later. 
Box-plot of Gas6 levels presented as median with interquartile range (IQR) and whiskers 
with maximum length of 1.5 IQR. T1, Gas6 level at the time of the index VTE of all patients 
(Gas6: n = 864). T1’ Gas6 level at the time of the index VTE of patients who also had Gas6 
level measured at T2 (Gas6: n = 601). T2, Gas6 level 12 months after the index VTE (Gas6: 
n = 601). The P value compared T1’ and T2 and is from a Wilcoxon matched pairs signed-
ranks test. The Spearman correlation between T1’ and T2 was rs = 0.33 for Gas6. 
 
Figure 3. Cumulative incidence of VTE, major bleedingand mortality for strata of Gas6. 
The cumulative incidence of VTE (A), major bleeding (B) and mortality (C) for strata of Gas6 
levels was estimated using the Kaplan-Meier method and compared survivor functions 
across groups by the logrank test. Gas6 levels were categorized based on the lower and 
upper quartile as low (< 109%), medium (109-157%) and high (> 157%). 
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TABLES 
 
Table 1. Patients characteristics at the time of the index VTE by Gas6 plasma level 
(above versus below or at median)  
 Characteristic
*
 All Gas6 above 
median (>129%) 
Gas6 below or at 
median (≤129%) 
P 
value 
     
n (%) or 
median (IQR) 
 
 
n (%) or 
median (IQR) 
 
  
Total number of patients, n n = 864 n = 435 n = 429   
Patient age, years  75.0 (69.0; 81.0)  76.0 (70.0; 82.0)  74.0 (69.0; 80.0)  0.001  
Sex (women)     388 (44.9%)        207 (47.6%)        181 (42.2%)     0.111  
VTE location                                                           0.053  
    distal DVT only      70 (8.1%)         29 (6.7%)         41 (9.6%)      
    proximal DVT     195 (22.6%)        111 (25.5%)         84 (19.6%)      
    pulmonary embolism     599 (69.3%)        295 (67.8%)        304 (70.9%)      
Type of VTE†                                                          <0.001  
    unprovoked     522 (60.4%)        242 (55.6%)        280 (65.3%)      
    provoked     185 (21.4%)         92 (21.1%)         93 (21.7%)      
    cancer-related     157 (18.2%)        101 (23.2%)         56 (13.1%)      
Current oestrogen therapy during 
the last 3 months
*
 
     27  (3.1%)          9  (2.1%)         18  (4.2%)     0.073  
Immobilization during the last 3 
months 
    190 (22.0%)        115 (26.4%)         75 (17.5%)     0.001  
Major surgery during the last 3 
months 
    131 (15.2%)         72 (16.6%)         59 (13.8%)     0.251  
Prior VTE     251 (29.1%)        125 (28.7%)        126 (29.4%)     0.837  
Presence of PTS
*,‡
     453 (52.4%)        251 (57.7%)        202 (47.1%)     0.003  
History of major bleeding
*
      89 (10.3%)         54 (12.4%)         35 (8.2%)     0.039  
Chronic liver disease      13 (1.5%)         10 (2.3%)          3 (0.7%)     0.053  
Renal disease
§
     170 (19.7%)         97 (22.3%)         73 (17.0%)     0.051  
Chronic or acute heart failure     103 (11.9%)         57 (13.1%)         46 (10.7%)     0.280  
Cerebrovascular disease (stroke, 
TIA) 
     84 (9.7%)         44 (10.1%)         40 (9.3%)     0.695  
Diabetes mellitus     137 (15.9%)         79 (18.2%)         58 (13.5%)     0.062  
BMI >30
*
     201 (23.3%)        107 (24.6%)         94 (21.9%)     0.360  
High risk of fall
*,ǁ
     406 (47.0%)        233 (53.6%)        173 (40.3%)    <0.001  
Acute rheumatic disease during 
the last 3 months 
     29 (3.4%)         17 (3.9%)         12 (2.8%)     0.365  
Inflammatory bowel disease      31 (3.6%)          9 (2.1%)         22 (5.1%)     0.016  
Severe infection or sepsis during 
the last 3 months 
     71 (8.2%)         42 (9.7%)         29 (6.8%)     0.121  
Anemia
*,¶
     335 (38.8%)        206 (47.4%)        129 (30.1%)    <0.001  
Platelet count <150 G/l
*
     132 (15.3%)         78 (17.9%)         54 (12.6%)     0.039  
Antiplatelet therapy
#
     275 (31.8%)        147 (33.8%)        128 (29.8%)     0.212  
Arterial hypertension     552 (63.9%)        289 (66.4%)        263 (61.3%)     0.116  
Heart rate ≥110 beats/min
*
      79 (9.1%)         49 (11.3%)         30 (7.0%)     0.031  
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Systolic BP <100 mmHg
*
      28 (3.2%)         13 (3.0%)         15 (3.5%)     0.664  
Respiratory rate ≥30/min
*
      28 (3.2%)         16 (3.7%)         12 (2.8%)     0.469  
Temperature <36°C
*
      65 (7.5%)         27 (6.2%)         38 (8.9%)     0.119  
Arterial oxygen saturation <90%
*
      93 (10.8%)         62 (14.3%)         31 (7.2%)     0.001  
 
Abbreviations: BP, blood pressure; BMI, body mass index; DVT, deep vein thrombosis; IQR, 
interquartile range, PTS, post-thrombotic syndrome; TIA, transient ischemic attack; VTE, venous 
thromboembolism. 
* 
Values were missing forestrogen therapy during the last 3 months (0.1%), presence of PTS (1.9%), 
history of major bleeding (0.1%), BMI>30 (0.6%), high risk of fall (0.1%), anemia (5.8%), platelet 
count (5.8%), heart rate ≥110 beats/min (2.1%), systolic BP <100 mmHg (1.6%), respiratory rate 
≥30/min (21.1%), temperature <36°C (7.8%), arterial oxygen saturation <90% (21.3%). 
† Provoked VTE is defined as immobilization, surgery, or estrogen therapy during last three months. 
Cancer is defined as any solid or hematologic cancer that required chemotherapy, radiation therapy, 
surgical treatment, or palliative treatment during the last 3 months. 
‡
 Defined as Villalta score >5 or presence of an ulcer on left or right side 
§ 
Chronic renal disease or creatinine clearance <30 mL/min 
ǁ 
Defined as answering yes to at least one screening questions: 1) Did you fall during the last year?;  
2) Did   you notice any problem with gait, balance, or mobility?  
¶
 Anemia= Hemoglobin <12g/dL for female or <13g/dL for male 
#
 Defined as antiplatelet therapy such as aspirin 100 to 300 mg daily, clopidogrel, prasugrel, or 
spirin/dipyridamol at the time of the index VTE 
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Table 2. Discriminative power of Gas6 plasma level for outcomes 
From the time of the index VTE (T1) onward using measurements performed at the time of VTE 
diagnosis (T1) 
 No events/ no patients C-statistics (95% confidence interval) P value* 
Gas6 at the time of 
VTE diagnosis 
   
VTE recurrence    
  Up to 6 months 24/864 0.67 (0.57 to 0.78) 0.001 
  Up to 12 months 48/864 0.61 (0.52 to 0.69) 0.010 
  Up to 24 months 83/864 0.58 (0.52 to 0.64) 0.010 
  Up to 36 months 100/864 0.56 (0.51 to 0.62) 0.031 
Major bleeding    
Up to 6 months 62/864 0.62 (0.55 to 0.69) <0.001 
Up to 12 months 82/864 0.60 (0.54 to 0.66) 0.001 
Up to 24 months 103/864 0.60 (0.55 to 0.65) <0.001 
Up to 36 months 118/864 0.60 (0.55 to 0.65) <0.001 
Overall mortality    
  Up to 6 months 77/864 0.73 (0.67 to 0.78) <0.001 
  Up to 12 months 97/864 0.71 (0.65 to 0.76) <0.001 
  Up to 24 months 149/864 0.70 (0.66 to 0.74) <0.001 
  Up to 36 months 170/864 0.69 (0.65 to 0.73) <0.001 
 
From 12 months after the index VTE (T2) onward using measurements performed 12 months after the 
index VTE (T2) 
 No events/ no patients C-statistics (95% confidence interval) P value* 
Gas6 12 months 
after the index VTE 
   
VTE recurrence    
  Up to 12 months 32/601 0.66 (0.56 to 0.75) 0.002 
  Up to 24 months 49/601 0.62 (0.54 to 0.71) 0.003 
Major bleeding    
Up to 12 months 18/601 0.58 (0.43 to 0.72) 0.294 
Up to 24 months 32/601 0.57 (0.47 to 0.68) 0.173 
Overall mortality    
  Up to 12 months 33/601 0.57 (0.47 to 0.68) 0.181 
  Up to 24 months 48/601 0.56 (0.48 to 0.65) 0.159 
 
Abbreviations: VTE, venous thromboembolism 
*The p-value is from a test of the null hypothesis of no discrimination (i.e. a c-statistics of 0.5).  
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Table 3. Association between Gas6 plasma level and VTE recurrence - from the time of the index VTE (T1) 
onward using Gas6 measured at the time of VTE diagnosis (T1)  
 
  n/N 
(%) 
Crude subhazard 
ratio  
(95% confidence 
interval) 
P value Adjusted 
subhazard 
ratio (95% 
confidence 
interval) 
P value 
Up to 6 months       
Gas6 at the time of 
the index VTE 
(categorized) 
Low 
(<109%) 
2/216 (0.9) Reference  Reference  
 Medium 
(109-157%) 
11/435 
(2.5) 
2.77 (0.61 to 
12.51) 
0.185 2.95 (0.62 to 
13.95) 
0.172 
 High 
(>157%) 
11/213 
(5.2) 
5.74 (1.27 to 
25.95) 
0.023 6.65 (1.44 to 
30.80) 
0.015 
Log-transformed 
Gas6 at the time of 
the index VTE 
Continuous 
(per log-unit) 
24/864 
(2.8) 
4.71 (1.98 to 
11.19) 
<0.001 5.04 (2.14 to 
11.88) 
<0.001 
Up to 12 months       
Gas6 at the time of 
the index VTE 
(categorized) 
Low 
(<109%) 
8/216 (3.7) Reference  Reference  
 Medium 
(109-157%) 
23/435 
(5.3) 
1.46 (0.65 to 3.25) 0.355 1.50 (0.66 to 
3.40) 
0.335 
 High 
(>157%) 
17/213 
(8.0) 
2.26 (0.98 to 5.23) 0.056 2.42 (1.00 to 
5.89) 
0.051 
Log-transformed 
Gas6 at the time of 
the index VTE 
Continuous 
(per log-unit) 
48/864 
(5.6) 
2.42 (1.12 to 5.24) 0.025 2.47 (1.08 to 
5.64) 
0.032 
 
Abbreviations: PE, pulmonary embolism; VTE, venous thromboembolism 
Adjustments: VTE recurrence was adjusted for age, cancer, provoked VTE, prior VTE, overt PE, renal 
disease, 
and periods of AC (oral or parenteral anticoagulation) as a time-varying covariate.(6, 41, 44-52) 
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Table 4. Association between Gas6 plasma level and major bleeding up to 6 months  
 
  n/N (%) Crude SHR 
(95%-CI) 
P 
value 
Adjusted SHR 
(95%-CI) 
P 
value 
From the time of the index VTE (T1) onward using Gas6 measured at the time of VTE diagnosis (T1) 
Gas6 at the time 
of the index VTE 
(categorized) 
Low 
(<109%) 
7/216 (3.2) Reference  Reference  
 Medium 
(109-157%) 
32/435 
(7.4) 
2.33 (1.03 to 
5.28) 
0.043 2.07 (0.89 to 
4.82) 
0.093 
 High 
(>157%) 
23/213 
(10.8) 
3.47 (1.49 to 
8.10) 
0.004 2.58 (1.04 to 
6.37) 
0.040 
Log-transformed 
Gas6 at the time 
of the index VTE 
Continuous (per 
log-unit) 
62/864 
(7.2) 
2.79 (1.42 to 
5.46) 
0.003 2.05 (0.95 to 
4.41) 
0.067 
 
Abbreviation: VTE, venous thromboembolism 
Adjustments: Major bleeding was adjusted for age, cancer, provoked VTE, prior VTE, overt PE, renal 
disease, history of major bleeding, anemia, antiplatelet therapy, and periods of AC as a time-varying 
covariate.(51, 59-73)  
 
 
 
Table  5. Association between Gas6 plasma level and overall mortality up to 36 months 
 
  n/N 
(%) 
Crude hazard 
ratio 
(95% 
confidence 
interval) 
P 
value 
Adjusted 
hazard ratio 
(95% 
confidence 
interval) 
P 
value 
From the time of the index VTE (T1) onward using Gas6 measured at the time of VTE diagnosis (T1) 
Gas6 at the time 
of the index VTE 
(categorized) 
Low (<109%) 20/216 
(9.3) 
Reference  Reference  
 Medium (109-157%) 73/435 
(16.8) 
1.96 (1.20 to 
3.19) 
0.007 1.69 (1.00 to 
2.84) 
0.048 
 High (>157%) 77/213 
(36.2) 
4.95 (3.04 to 
8.05) 
<0.001 3.44 (2.03 to 
5.82) 
<0.001 
Log-transformed 
Gas6 at the time 
of the index VTE 
Continuous (per log-
unit) 
170/864 
(19.7) 
7.21 (4.48 to 
11.60) 
<0.001 5.00 (3.16 to 
7.92) 
<0.001 
From the time of the index VTE onward using Gas6 as a time-varying covariate (at the time of the 
index VTE and 12 months later) 
Gas6 time-
varying covariate 
(categorized) 
Low (<109%)  Reference  Reference  
 Medium (109-157%)  1.88 (1.26 to 
2.80) 
0.002 1.68 (1.09 to 
2.57) 
0.017 
 High (>157%)  5.55 (3.63 to 
8.47) 
<0.001 3.55 (2.21 to 
5.71) 
<0.001 
Log-transformed 
Gas6 time-
varying covariate 
Continuous (per log-
unit) 
 8.50 (5.51 to 
13.11) 
<0.001 5.18 (3.17 to 
8.46) 
<0.001 
 
Abbreviations: VTE, venous thromboembolism 
Adjustments: Mortality was adjusted for age, gender, cancer, provoked VTE, prior VTE, overt PE, 
renal disease, history of major bleeding, heart failure, chronic lung disease, high pulse, low blood 
pressure, low oxygen, and periods of anticoagulation as a time-varying covariate.(49, 53)  
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